Comparative Pharmacology
Head-to-head clinical analysis: CANTIL versus TROPICAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANTIL versus TROPICAMIDE.
CANTIL vs TROPICAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Antimuscarinic agent that blocks acetylcholine at muscarinic receptors in the ciliary muscle and sphincter muscle of the iris, resulting in mydriasis and cycloplegia.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
1-2 drops of 0.5% or 1% solution topically in the eye(s), repeated in 5 minutes if needed for maximal effect; for cycloplegic refraction, 1-2 drops of 1% solution repeated in 5 minutes.
None Documented
None Documented
Clinical Note
moderateTropicamide + Fesoterodine
"The risk or severity of adverse effects can be increased when Tropicamide is combined with Fesoterodine."
Clinical Note
moderateTropicamide + Quinidine
"The risk or severity of adverse effects can be increased when Tropicamide is combined with Quinidine."
Clinical Note
moderateTropicamide + Darifenacin
"The risk or severity of adverse effects can be increased when Tropicamide is combined with Darifenacin."
Clinical Note
moderateTropicamide + Topiramate
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Terminal elimination half-life is approximately 2 hours; clinically, mydriasis and cycloplegia persist for 4-8 hours despite rapid plasma clearance.
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Primarily renal excretion of unchanged drug and metabolites; approximately 30% unchanged in urine within 6 hours; minor biliary/fecal elimination (<5%).
Category C
Category A/B
Anticholinergic / Antispasmodic
Anticholinergic
"The risk or severity of adverse effects can be increased when Tropicamide is combined with Topiramate."